It has been established that glioblastoma (GBM) survival differs by sex, with females having a significant survival advantage.¹ Another prognostic factor associated with GBM survival is O⁶-methylguanine-DNA methyltransferase (MGMT) promoter methylation, associated with sensitivity to alkylating chemotherapy, such as temozolomide (TMZ), and improved survival.^2,3MGMT methylation status impacts treatment patterns for GBM. Studies suggest that patients with unmethylated tumors should receive only radiotherapy.⁴ Here, we investigate, utilizing a large real-world data set, the impact of MGMT methylation status on sex-specific survival for different GBM treatment patterns.